Papers/PMID:35997951
Effects of L-carnitine supplementation in patients with mild-to-moderate COVID-19 disease: a pilot study.
Pharmacological reports : PR2022The record
1 finding · 1 compound · 1 endpoint
What it reported
How to read these marksWhat moved
1 finding
(R)-carnitine — decreases C-reactive protein concentration
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding“In addition, mean ESR and CRP, as indicators of inflammation, were significantly lower in the intervention group compared to the control (p = 0.021 and p = 0.009, respectively; two-sided T-test).”
Quoted verbatim from Effects of L-carnitine supplementation in patients with mild-to-moderate COVID-19 disease: a pilot study.. - Study
- RCT
- Duration
- 5 days
- Dose
- 1000 mg oral every 8 h (3 g daily) added to routine treatment
- Population
- Hospitalised adults aged 18 to 60 with mild-to-moderate COVID-19, all on routine hospital treatment including remdesivir, beta-interferon and dexamethasone
Effects of L-carnitine supplementation in patients with mild-to-moderate COVID-19 disease: a pilot study.2022PMID:35997951Permalink